Journal of Andrology Testis Workshop 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published-Ahead-of-Print May 28, 2009, DOI:10.2164/jandrol.108.007278

This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
30/6/679    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Efesoy, O.
Right arrow Articles by Akbay, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Efesoy, O.
Right arrow Articles by Akbay, E.

The Efficacy of Recombinant Human Follicle-Stimulating Hormone in the Treatment of Various Types of Male Factor Infertility at a Single University Hospital

Ozan Efesoy , Selahittin Çayan *, and Erdem Akbay

* To whom correspondence should be addressed. E-mail: selcayan{at}mersin.edu.tr.

The aim of the study was to prospectively investigate the efficacy of recombinant human follicle-stimulating hormone (rhFSH) in the treatment of various types of male factor infertility at a single university hospital. The study included 61 infertile men receiving rhFSH due to various type of male infertility. Treatment included 100-150 IU of rhFSH for 2-3 times/week. All men were divided into 4 groups as hypogonadotropic hypogonadism (n=21), isolated FSH deficiency (n=13), idiopathic oligoasthenospermia (n=16) and maturation arrest on testicular biopsy (n=11). Total motile sperm count (TMSC), serum FSH level and testicular volume were compared before and after the treatment in all groups. In the hypogonadotropic hypogonadism group, spermatozoa appeared in the ejaculate, with a mean of 6.67 ± 1.57 million TMSC, in 15 of 21 patients (71.4%) who were totally azoospermic before the treatment. In the isolated FSH deficiency group, TMSC significantly increased from 6.64 ± 3.27 to 32.4 ± 9.09 million after the treatment (p=0.003). TMSC did not significantly increase in the idiopathic oligoasthenospermia group. Two of the men with maturation arrest (18.1%) had spermatozoa in the ejaculate after the treatment. rhFSH therapy may be effectively used to improve sperm parameters in infertile men with hypogonadotropic hypogonadism and isolated FSH deficiency. In addition, rhFSH may have some improvement by either providing sperm in ejaculate or increasing ICSI success in infertile men with maturation arrest.


Key words: Hormone • Infertility • Semen Analysis • Sperm • Spermatogenesis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2009 by The American Society of Andrology.